Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

by Jin-Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiao-Jie Lu, Jiansong Ji
Published 2020-08-01

Assessment of tumor mutation burden calculation from gene panel sequencing data

by Xu Z, Dai J, Wang D, Lu H, Dai H, Ye H, Gu J, Chen S, Huang B
Published 2019-05-01

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin

by Shaomeng Chen, Xiuman Zhou, Xin Yang, Wanqiong Li, Shuzhen Li, Zheng Hu, Chen Ling, Ranran Shi, Juan Liu, Guanyu Chen, Nazi Song, Xianxing Jiang, Xinghua Sui, Yanfeng Gao
Published 2021-09-01

Identification ACTA2 and KDR as key proteins for prognosis of PD‐1/PD‐L1 blockade therapy in melanoma

by Yuchen Wang, Zhaojun Li, Zhihui Zhang, Xiaoguang Chen
Published 2021-06-01

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis

by Pierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, Andrea Sergi, Maria Antonietta Mazzei, Giovanna Bianco, Rocco Giannicola, Eleonora Iuliano, Iris Maria Forte, Natale Daniele Calandruccio, Antonia Consuelo Falzea, Alessandra Strangio, Valerio Nardone, Pierpaolo Pastina, Paolo Tini, Amalia Luce, Michele Caraglia, Daniele Caracciolo, Luciano Mutti, Pierfrancesco Tassone, Luigi Pirtoli, Antonio Giordano, Pierosandro Tagliaferri
Published 2020-08-01

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies

by Dongxu Wang, Jianzhen Lin, Xu Yang, Junyu Long, Yi Bai, Xiaobo Yang, Yilei Mao, Xinting Sang, Samuel Seery, Haitao Zhao
Published 2019-04-01

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade

by Tomoko Aoki, Masatoshi Kudo, Kazuomi Ueshima, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Hiroshi Ida, Yasunori Minami, Masakatsu Tsurusaki, Naoshi Nishida
Published 2020-10-01

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

by Fei Tang, Pan Zheng
Published 2018-05-01

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

by Zhenqing Wang, Liang Chen, Yiqun Ma, Xilei Li, Annan Hu, Huiren Wang, Wenxing Wang, Xiaomin Li, Bo Tian, Jian Dong
Published 2021-08-01